在PEPFAR治疗计划中使用仿制抗逆转录病毒药物和节省成本
Charles B Holmes1, William Coggin, David Jamieson
1Office of the US Global AIDS Coordinator, US Department of State, Washington, DC 20522-2920, USA. holmescb@state.gov
JAMA
|July 20, 2010
概括
通用抗逆转录病毒药物 (ARV) 的可用性在PEPFAR支持的计划中显著增加了ARV采购. 这一转变带来了巨大的成本节约,证明了通用ARV在全球卫生倡议中的价值.
科学领域:
- 全球健康 全球健康
- 药物经济学 药物经济学
- 艾滋病毒/艾滋病 治疗
背景情况:
- 抗逆转录病毒药物 (ARV) 的高成本阻碍了发展中国家的治疗规模扩大.
- 美国食品和药物管理局 (FDA) 加快了通用ARV的批准,增加了诸如美国总统艾滋病救援紧急计划 (PEPFAR) 等计划的可用性.
研究的目的:
- 评估在非洲,圭亚那,海地和越南的PEPFAR支持计划中采用仿制抗病毒药物的情况.
- 分析随着时间的推移,ARV利用和相关成本的变化.
主要方法:
- 从2005年到2008年在16个PEPFAR支持国家的ARV采购的年度调查.
- 评估药品支出,ARV类型,数量,通用采购比例和成本节省.
主要成果:
- 通用ARV采购量从2005年的14.8%大幅上升到2008年的89.33%.
- 到2008年,估计的成本节约达到3.23亿美元.
- 观察到ARV支出和采购量显著增加.
结论:
- 通用ARV的可用性与PEPFAR计划中ARV采购量的增加相关.
- 通过增加通用ARV的使用,可以实现大幅度的成本节约.
相关概念视频
Retrovirus Life Cycles
43.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
43.0K
Retroviruses
12.1K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
12.1K
Pulmonary Tuberculosis V
1.0K
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
1.0K
Pharmacokinetics in Pediatric Patients: Drug Excretion
408
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97


